Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

• 2025 Truist Securities BioPharma Symposium
  Dr. Gabriel Brooks, Chief Medical Officer, will participate in a panel discussion titled “Precision Medicine: DMD, FA, and Beyond” on Thursday, November 6, 2025, at 1:40 p.m. ET.

• 2^nd Annual Guggenheim Healthcare Innovation Conference
  Members of management will participate in 1x1 investor meetings on Monday, November 10, 2025.

Institutional investors interested in one-on-one meetings with management during the conferences may reach out to their Truist or Guggenheim representatives.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
[email protected]

Media Contact:
Glenn Silver
FINN Partners
[email protected]

You May Also Be Interested In

• Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
• ChronoTech AI Inc. Launches Intelligent Robotics Platform
• Crypto Fear Index Drops to 37, Best Crypto To Buy Now Buyers Hunt AlphaPepe Before Risk Appetite Returns